Evidence map›Paper›PMID 40200290›Full record

ArticleBMC medicine2025

Bile acid metabolism in multiple sclerosis is perturbed and associated with the risk of confirmed disability worsening.

Ida Erngren, Aina Vaivade, Henrik Carlsson, Asma Al-Grety, Torbjörn Åkerfeldt, Ingrid Kockum, Anna Karin Hedström, Lars Alfredsson, Tomas Olsson, Joachim Burman and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Emerging Roles of Bile Acids in Neuroinflammation.International journal of molecular sciences · 2025
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ida ErngrenDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Akademiska Sjukhuset, entrance 61, 3rd floor, Uppsala, 75185, Sweden.
Aina VaivadeDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Akademiska Sjukhuset, entrance 61, 3rd floor, Uppsala, 75185, Sweden.
Henrik CarlssonDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Akademiska Sjukhuset, entrance 61, 3rd floor, Uppsala, 75185, Sweden.
Asma Al-GretyDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Akademiska Sjukhuset, entrance 61, 3rd floor, Uppsala, 75185, Sweden.
Torbjörn ÅkerfeldtDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Akademiska Sjukhuset, entrance 61, 3rd floor, Uppsala, 75185, Sweden.
Ingrid KockumDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Anna Karin HedströmDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Lars AlfredssonDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Tomas OlssonDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Joachim BurmanDepartment of Medical Sciences, Translational Neurology, Uppsala University, Uppsala, Sweden.
Kim KultimaDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Akademiska Sjukhuset, entrance 61, 3rd floor, Uppsala, 75185, Sweden. Kim.Kultima@medsci.uu.se.

Funding

FORTE 2024-01410Svenska Forskningsrådet Formas 2020-01267Svenska Läkaresällskapet SLS-59352Vetenskapsrådet 2021-02189Vetenskapsrådet 2021-02814
6 · The paper itself

Abstract

backgroundBile acids (BAs) have emerged as important mediators in neuroinflammation and neurodegeneration, important features of multiple sclerosis (MS). This study aimed to examine serum BA levels in newly diagnosed people with MS (pwMS) and explore their association with disability worsening.

methodsThe study included 907 pwMS and 907 matched controls from the Swedish population-based EIMS cohort, with clinical follow-up data from the Swedish MS Registry. Serum BA levels were analyzed using liquid chromatography-high-resolution mass spectrometry. Differential expression analysis was used to study differences in BAs between pwMS and controls. Cox proportional-hazard models were used to assess associations between BA concentrations and confirmed disability worsening (CDW) and the risk of reaching EDSS milestones 4.0 and 6.0.

resultsPwMS had lower concentrations of the primary conjugated BA, glycochenodeoxycholic acid (GCDCA, log

conclusionsThis study identified alterations in serum BA profiles in pwMS compared to controls, with strong associations between conjugated BAs and the risk of disability worsening. These findings underscore the potential role of BAs in MS pathogenesis and disability worsening, suggesting they may be promising targets for future therapeutic interventions. Further research is warranted to clarify the underlying mechanisms of these associations.

Indexed as

Bile Acids and SaltsMultiple SclerosisAdultCase-Control StudiesDisability EvaluationDisease ProgressionFemaleHumansMaleMiddle AgedSwedenBile Acids and SaltsAutoimmune disorderBile acidsConfirmed disability worseningMultiple sclerosis

Identifiers

PMID40200290
PMCPMC11980154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.